
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions is set to benefit from the opening of the Aby J. Mathew Center for Biopreservation Excellence, showcasing their full product portfolio and supporting research efforts for new cryopreservation products. With an impressive revenue growth of 31% in Q3 and strong market share in their biopreservation media, the recent divestment of their evo business will further streamline the company and allow for continued growth and margin expansion. BioLife's FY2025 revenue guidance and expected reduction in net loss further solidifies our positive outlook on the company's financials.
Bears say
BioLife Solutions is currently in a strong cash position, with $98.4 million in cash and marketable securities as of September 2025. However, the company's cash flows from operating activities were only $6.1 million in 3Q25 and its adjusted EBITDA was approximately $7.8 million, suggesting that its profitability may be limited in the short term. Additionally, while the company has a solid revenue stream from its Cell Processing segment, there may be potential risks and challenges in the rapidly evolving field of cell and gene therapy that could impact its growth and future earnings potential.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares